NVS-SM2 treatment increased human SMN protein levels by 4.5-fold in brain (P = 0.0005), and 2.5-fold in spinal cord (P = 0.0355) and in muscle tissues in severe SMA mice (Figs 1A–C and S2A and B). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.